Latest European Market News

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Energy One Limited (ASX – EOL) delivered a robust FY25 performance, posting 17% revenue growth to $61.4 million alongside a 74% surge in net profit, underpinned by strong market expansion and strategic investments in cybersecurity and product innovation.

Sarytogan Graphite Limited secures a strategic A$3.6 million investment from Kazakh high-net-worth investor Dias Sarsenov, accelerating its Definitive Feasibility Study for a critical graphite project vital to Europe’s raw materials supply.

Orbital Corporation has denied any undisclosed information behind its recent share price jump, attributing market interest to strategic leadership appointments aimed at expanding its UAV propulsion business.

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

AML3D has appointed German firm DMFG Solutions as a second European distributor, complementing its recent UK partnership and supporting a AU$5 million investment in a new technology centre.

Surefire Resources NL has progressed drilling at its Yidby Gold Project with promising metallurgical results, while advancing development of its Victory Bore critical minerals deposit. The company also launched a capital raising to support ongoing exploration and development.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

South Harz Potash has completed a partial entitlement offer raising A$566,000, with directors backing the raise, as it pushes to secure the full A$3.11 million to fund its dual-asset growth strategy in Germany.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

Sprintex has advanced a promising trial with a major Dutch agribusiness, potentially unlocking €4.8 million in sales, while also securing a significant private-label contract in China’s booming aquaculture sector.

Firebird Metals has made significant strides in its lithium manganese iron phosphate (LMFP) battery strategy, unveiling a new lab-scale cathode production facility and securing key patents. The company also demonstrated major energy savings in kiln trials, positioning itself strongly in the evolving battery materials market.